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Background: While HLA-antibodies (Ab) have an estab-
lished role in failed engraftment after single-unit CB trans-
plantation (CBT), their role in double-unit CBT (DCBT)
engraftment is more controversial.
Methods:We evaluated the inﬂuence of pre-transplant HLA-
Ab on sustained donor neutrophil engraftment & unit
dominance in 82 recipients (median age 48, range 2-69) of 4-
6/6 HLA-A,B antigen, DRB1 allele matched double-unit CB
grafts, & transplanted for hematologic malignancies from 7/
2008-7/2012. HLA-Ab were measured by the American Red
Cross Blood Service using Single Antigen Luminex beads &
analyzed by HLA Fusion software. The cut-off for positive
results was a normalized mean ﬂuorescence intensity value
> 1000.
Results: 28/82 (34%) patients were positive for HLA-Ab [16
(19.5%) had Ab without graft speciﬁcity, & 12 (14.5%) had Ab
with graft speciﬁcity]. These patients were more likely to be
female with acute leukemia & CMV seropositive. All patients
with graft-speciﬁc Ab receivedmyeloablative conditioning; 5
had Ab against class I HLA, 6 against class II, & one patient
had Ab to both Class I/II. Moreover, of these 12 patients, 6 had
Ab against one unit & 6 had Ab against both units. Neutrophil
engraftment according to Ab is summarized in the Table.Table
Sustained Donor Neutrophil Engraftment According to HLA-Ab
1A) Myeloablative Conditioning (n ¼ 67)
Median (Range)
Time to Neutrophil
Recovery (0.5)
N (%) Sustained
Engraftment
No Ab (n ¼ 41) 23 days (range 12-38) 39/40
(1 non-evaluable)
Ab: not graft-speciﬁc
(n ¼ 14)
23 days (range 12-37) 14/14
Ab: graft-speciﬁc
(n ¼ 12)
31 days (range 13-40) 11/12
Against engrafting unit
(n ¼ 3)
28 days (range 24-31) 3/3
Against non-engrafting
unit (n ¼ 3)
31 days (range 25-32) 3/3
Against both units
(n ¼ 6)
33 days (range 13-40) 5/6
1B) Non-Myeloablative Conditioning (n ¼ 15)
Median (Range)
Time to Neutrophil
Recovery ( 0.5)
N (%) Sustained
Engraftment
No Ab (n ¼ 13) 10 days (range 8-20) 13/13
Ab: not graft speciﬁc
(n ¼ 2)
19 days in 1 patient
(other had autologous
recovery)
1/2
Ab: graft speciﬁc (n ¼ 0) - -64/66 (97%) evaluable myeloablative DCBT recipients (Table
1A) engrafted at a median of 24 days (range 12-40); one
patient without Ab & one with Ab against both units had
primary graft failure, both in the setting of early onset multi-
organ failure. Both patients were 100% donor in the marrow
with one unit but did not recover counts. Of the 6 patients
with Ab to one unit, 3 engrafted with that unit & 3 with the
opposite unit. Of the 6 patients with Ab against both units,
one had clinical graft failure as described above, & the 5
others had sustained donor engraftment (4 with one unit &
one with both). In engrafting myeloablative recipients, the
median time to neutrophil recovery was 8 days slower in
patients with graft-speciﬁc Ab, but the engrafting unit in
these patients also had the lowest infused dose: median
CD34+ cell dose/kg if no Ab 0.83 x 105/kg, non-speciﬁc Ab
1.09 x 105/kg, & Ab speciﬁc to graft 0.65 x 105/kg. In non-
myeloablative recipients, 15/16 (94%) engrafted (Table 1B).
The single patient with rejection/ autologous recovery had
Ab that were not graft speciﬁc.
Conclusions: 11/12 double-unit CBT recipients with graft-
speciﬁc Ab engrafted successfully. While myeloablative
recipients with graft-speciﬁc Ab engrafted more slowly, this
may be explained by their lower infused CD34+ cell dose.
While multivariate analysis of larger series will be required
to further evaluate the effect of graft-speciﬁc Ab on
engraftment speed, currently the presence of graft-speciﬁc
Ab should not preclude DCBT, & whether their presence
should inﬂuence graft selection is unclear. Moreover, there is
no suggestion that HLA-Ab inﬂuence unit dominance after
DCBT.
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The Effect of Donor Characteristics on Graft vs. Host
Disease (GVHD) and Survival after Unrelated Donor Trans-
plantation for Hematologic Malignancy.
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We analyzed 6,349 adult unrelated donor trans-
plantations performed in 1988e2006 to reexamine the effect
of donor age and other donor characteristics including
donor-recipient HLA matching on transplant outcomes.
